☆ 4.7 Review

Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug ef6cacies

PHARMACOLOGY & THERAPEUTICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

R. A. Sooy et al.

Summary: This study investigated the efficacy and safety of combined osimertinib and bevacizumab compared to osimertinib alone in patients with EGFR-mutant advanced NSCLC. The results showed no significant difference in PFS, OS, and ORR between the combination treatment and osimertinib monotherapy. Grade >= 3 TRAEs were more common in patients receiving the combination treatment.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

J. Niu et al.

Summary: The study investigated the safety and efficacy of the anti-TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. The combination therapy showed promising antitumor activity in patients with NSCLC and those refractory to anti-PD-1/PD-L1 treatment.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis

Hong-Xia Wu et al.

Summary: HER2-targeted therapy shows varied efficacy in treating HER2-positive NSCLC, with ADC (DS-8201), pyrotinib, and poziotinib demonstrating promising anti-tumor activity. In particular, higher ORRs and DCRs were observed in the poziotinib and pyrotinib groups. The study suggests that HER2-targeted therapy may be a viable treatment option for NSCLC patients with HER2 alterations.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Article Oncology

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC

Erica C. Nakajima et al.

Summary: The FDA has granted accelerated approval to sotorasib for the treatment of advanced non-small cell lung cancer with a KRAS G12C mutation. The drug has shown significant overall response rate and duration of response in clinical trials, with common adverse reactions including diarrhea and musculoskeletal pain.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC

Oladimeji Akinboro et al.

Summary: The FDA's approval of cemiplimab-rwlc as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC) is supported by significant improvements in overall survival in international clinical trials. These single-agent anti-PD-L1 antibodies have demonstrated comparable efficacy and manageable safety profiles.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer

Simon Vyse et al.

Summary: Amivantamab is a monoclonal bispecific anti-EGFR-MET antibody approved for NSCLC patients with EGFR exon 20 insertion mutations, which are typically associated with poor outcomes. It has dual activity against EGFR and MET, with potential implications for toxicity, efficacy, and drug resistance mechanisms. Future trials will focus on combination treatments with brain-penetrant EGFR kinase inhibitors to possibly improve outcomes for these patients.

EXPERT REVIEW OF ANTICANCER THERAPY (2022)

添加到收藏夹

Article Oncology

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

Julien Mazieres et al.

Summary: This study evaluated the efficacy of a triple therapy with HER2-targeted antibodies and docetaxel in HER2-mutated NSCLC patients, demonstrating feasibility and effectiveness of this approach, highlighting the potential benefit of HER2 antibody-based strategy in this subset of patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Xiuning Le et al.

Summary: Poziotinib demonstrates antitumor activity in previously treated patients with HER2 exon 20 insertion NSCLC, showing significant tumor reduction, high disease control rate, and prolonged duration of response.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Caicun Zhou et al.

Summary: The GEMSTONE-302 trial showed that sugemalimab plus chemotherapy significantly improved progression-free survival in previously untreated squamous and non-squamous metastatic NSCLC patients compared to placebo plus chemotherapy, regardless of PD-L1 expression. These findings have important implications for the first-line treatment of squamous and non-squamous metastatic NSCLC.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial

Mariona Riudavets et al.

Summary: This study evaluated the safety and efficacy of the combination of tremelimumab and gefitinib in patients with EGFR-mutant NSCLC. The results showed limited efficacy with this combination, with stable disease being the best overall response in most patients. Gastrointestinal toxicity was the main adverse reaction.

LUNG CANCER (2022)

添加到收藏夹

Article Oncology

Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach

S. Marks et al.

Summary: This review provides an overview of the design, mode of action, and mechanisms of resistance to antibody-drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC). The clinical development of several promising ADCs in early phase clinical trials for NSCLC treatment is also summarized, along with the exploration of combination strategies to overcome resistance to ADC therapy.

LUNG CANCER (2022)

添加到收藏夹

Article Oncology

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations

Luckson N. Mathieu et al.

Summary: The FDA has approved capmatinib and tepotinib as new treatments for metastatic non-small cell lung cancer with MET exon 14 skipping alterations. Clinical trials have shown that both drugs have demonstrated effectiveness in treating patients with metastatic NSCLC.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Review Oncology

Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences

Ling Chen et al.

Summary: This article reviews the research advances of three third-generation EGFR-TKIs, namely osimertinib, almonertinib, and furmonertinib, in terms of pharmacokinetics, pharmacodynamics, treatment-related adverse events, and other aspects. Individualized optimization of third-generation EGFR-TKIs options may provide maximum benefits to NSCLC patients with EGFR T790M mutation.

CANCER INVESTIGATION (2022)

添加到收藏夹

Review Oncology

A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)

Ziad Abuhelwa et al.

Summary: Although targeted and immunotherapy-based therapies are standard treatments for advanced lung cancer, chemotherapy remains a viable salvage option for adverse events, resistance, and disease progression. Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies and the cytotoxic effects of chemotherapy to directly deliver cytotoxic payloads to cancer cells. Trastuzumab ematansine and trastuzumab deruxtecan are key ADC drugs used in advanced solid tumors.

CANCER TREATMENT REVIEWS (2022)

添加到收藏夹

Article Oncology

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design

Gregory J. Riely et al.

Summary: BRAF(V600) mutations occur in 1-2% of NSCLC patients, and combination therapy with BRAF and MEK inhibitors has shown potential efficacy. The ongoing PHAROS trial aims to evaluate the antitumor activity and safety of encorafenib plus binimetinib in patients with metastatic BRAF(V600)-mutant NSCLC.

FUTURE ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Diego de Miguel-Perez et al.

Summary: This study evaluated the use of extracellular vesicle PD-L1 expression as a biomarker for predicting durable treatment response and survival in non-small cell lung cancer (NSCLC) patients receiving immune-checkpoint inhibitors (ICIs). The results showed that an increase in extracellular vesicle PD-L1 was observed in non-responders compared to responders and was an independent biomarker for shorter progression-free survival and overall survival. In contrast, tissue PD-L1 expression, the commonly used biomarker, was not predictive for durable response or survival.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Review Chemistry, Physical

Next-generation cancer organoids

Bauer L. LeSavage et al.

Summary: The translation discusses how organotypic models of patient-specific tumors are changing our understanding of cancer heterogeneity and personalized medicine. These models can preserve genetic, proteomic, morphological, and pharmacotypic features of the parent tumor in vitro, and offer genomic and environmental manipulation. However, current cancer organoid culture techniques are uncontrolled and irreproducible, hindering the acceleration of insights into patient care.

NATURE MATERIALS (2022)

添加到收藏夹

Editorial Material Oncology

The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC

Fen Wang et al.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Byoung Chul Cho et al.

Summary: The combination of tiragolumab and atezolizumab showed promising efficacy and safety as first-line treatment for NSCLC, with improved objective response rate and progression-free survival compared to placebo plus atezolizumab.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy

Anna Minchom et al.

Summary: In patients with advanced NSCLC harboring EGFR exon 20 insertion mutations, treatment with amivantamab resulted in improved outcomes compared to external controls, including longer progression-free survival, time to next therapy, and overall survival.

LUNG CANCER (2022)

添加到收藏夹

Review Oncology

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors

Jacob J. Adashek et al.

Summary: BRAF V600 mutations are prevalent in various nonmelanoma malignancies and can be clinically targeted with BRAF inhibitor therapy, suggesting their potential application in the treatment of nonmelanoma rare malignancies in both adults and children.

MOLECULAR CANCER THERAPEUTICS (2022)

添加到收藏夹

Article Immunology

TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy

Kirsten De Ridder et al.

Summary: Immune checkpoint blockade of the PD-1 pathway has greatly improved the survival prognosis for advanced non-small cell lung cancer (NSCLC). However, many PD-L1(+) NSCLC patients are resistant to anti-PD-L1 therapy. This study found that PD-L1(+) tumor-infiltrating myeloid cells play a crucial role in the failure of therapy. Anti-PD-L1 therapy induced a monocyte-specific production and response to TNF-alpha, accompanied by increased expression of CD80, VISTA, LAG-3, SIRP-alpha, and TIM-3. However, co-blockade of PD-L1 and TNF-alpha did not reduce tumor growth.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy

Timothy Rajakumar et al.

Summary: Immunotherapies have shown great efficacy in a subset of late-stage cancers, but only a minority of patients benefit from these therapies. The use of tissue-based PD-L1 expression as a predictor of response is limited, highlighting the need for more accurate biomarkers. Through the analysis of whole blood microRNA, we identified a peripheral blood biomarker (miRisk score) that can predict response to immunotherapies against lung cancer, outperforming tissue-based PD-L1 staining.

NPJ PRECISION ONCOLOGY (2022)

添加到收藏夹

Editorial Material Oncology

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations

M. Blaszkowska et al.

ESMO OPEN (2022)

添加到收藏夹

Article Oncology

Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).

Si-Yang Maggie Liu et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Extracellular vesicles in cancer therapy

Shizhen Emily Wang

Summary: Extracellular vesicles (EVs) play a major role in intercellular communication in both physiological and pathological processes. Tumor-derived EVs contribute to cancer cell plasticity and resistance to therapy, adaptation of tumor microenvironment, vascular remodeling, immunomodulation, and establishment of pre-metastatic niches. Therefore, studying EVs and developing targeted therapies and diagnostic methods based on EVs is of great importance for cancer treatment.

SEMINARS IN CANCER BIOLOGY (2022)

添加到收藏夹

Article Oncology

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines

Timothee Olivier et al.

Summary: This study discusses the questions regarding the unmet need within the accelerated approval pathway, the lack of equipoise between new compounds and existing options, the unsupported recommendation by NCCN, and the insufficient clarity provided by postmarketing requirements. The study has implications beyond patients with exon 20 insertion, as it can prevent the misguided incorporation of new compounds into clinical practice.

TRANSLATIONAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial

Dean A. Fennell et al.

Summary: This study investigates the relationship between HRD modification and the sensitivity to PARP inhibitor olaparib in patients with metastatic non-small cell lung cancer who exhibited partial responses to platinum doublet-based chemotherapy.

ECLINICALMEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology

Aniko Zeold et al.

Summary: Extracellular vesicles (EV) are considered a potential diagnostic tool for pancreatic ductal adenocarcinoma (PDAC), with PDAC patient-derived organoids serving as an ideal in vitro model for studying human cancers. The miRNA composition of EVs varies among patients, but there are common miRNA sets in matched organoids and blood plasma samples. Levels of miR-21 and miR-195 in PDAC blood EVs are elevated compared to healthy controls, suggesting a potential biomarker for the disease.

CELLULAR AND MOLECULAR LIFE SCIENCES (2021)

添加到收藏夹

Article Engineering, Biomedical

A novel design of microfluidic platform for metronomic combinatorial chemotherapy drug screening based on 3D tumor spheroid model

Sharanya Sankar et al.

Summary: Combining chemotherapy drugs for cancer treatment can yield better results with fewer side effects, but finding the right drug combinations is challenging. A novel microfluidic device has been developed to test different combinations of drugs on lung tumor spheroids, potentially leading to more effective and less toxic treatments for cancer patients. The device could also be used for personalized medicine by testing patient-specific tumor spheroids and identifying synergistic drug combinations.

BIOMEDICAL MICRODEVICES (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

Tony S. Mok et al.

Summary: This study provides an updated analysis of overall survival in patients with advanced NSCLC and EGFR-activating mutations treated with dacomitinib versus gefitinib. The OS benefit from first-line treatment with dacomitinib was maintained after extended follow-up, indicating its efficacy in this patient population.

DRUGS (2021)

添加到收藏夹

Article Oncology

Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics

Cristina E. Tognon et al.

Summary: The use of ex vivo drug sensitivity testing has been actively explored for almost 50 years, especially in cancer research, and despite extended failures, it has proven to be crucial in the development of transformational drugs.

ANNUAL REVIEW OF CANCER BIOLOGY, VOL 5, 2021 (2021)

添加到收藏夹

Review Oncology

Challenges of applying multicellular tumor spheroids in preclinical phase

Se Jik Han et al.

Summary: The three-dimensional multicellular tumor spheroids model has great potential for cancer research, resembling in vivo solid tumors in many aspects and providing a platform for studying biological properties of tumors and drug screening. However, challenges in adoption for preclinical studies remain to be addressed.

CANCER CELL INTERNATIONAL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids

Seon Young Choi et al.

Summary: The study generated patient-derived tumor organoids from small cell lung cancer and found that the organoids maintained similar characteristics to the patient tumor tissue even after long-term expansion. The differential response of the organoids to chemotherapy drugs due to cellular heterogeneity could be utilized for investigating tumor recurrence mechanisms and developing personalized medicine.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article

Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids

Dylan AJ Gendre et al.

Oncotarget (2021)

添加到收藏夹

Review Oncology

Primary Lung Cancer Organoids for Personalized Medicine-Are They Ready for Clinical Use?

Raphael S. Werner et al.

Summary: Research on NSCLC organoids as in vitro models is gaining momentum, offering a more representative and complex system compared to standard two-dimensional cell culture models.

CANCERS (2021)

添加到收藏夹

Review Oncology

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations

M. Riudavets et al.

Summary: NSCLC with HER2 alterations is now recognized as a distinct subtype, with different mechanisms of HER2 activation and varying responses to treatment options. While nonselective TKIs have shown limited benefit, novel HER2 TKIs and ADCs are showing promising activity in HER2-mutant NSCLC patients, indicating a shift towards combination therapies with different mechanisms of action for better management of HER2-altered NSCLC.

ESMO OPEN (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week

Yawei Hu et al.

Summary: The time-consuming nature of establishing patient-derived organoids (PDOs) hinders their implementation in clinic-based drug sensitivity tests, but a microwell array-based method was shown by the authors to predict patient responses to anti-cancer therapies within a week using lung cancer organoids.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Liquid Biopsy for Colorectal Adenoma: Is the Exosomal miRNA Derived From Organoid a Potential Diagnostic Biomarker?

Tomoyuki Handa et al.

Summary: Exosomal miRNAs derived from CRA organoid culture could be potential diagnostic biomarkers for CRA.

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2021)

添加到收藏夹

Article Oncology

Clinical application of a lung cancer organoid (tumoroid) culture system

Etsuko Yokota et al.

Summary: By utilizing AO media developed by the Clevers laboratory, researchers successfully established long-term cultured lung tumoroid lines from lung cancer cases, each carrying distinct mutations. Targeted therapies with small molecule drugs significantly suppressed the growth of lung tumoroid lines driven by specific genetic alterations.

NPJ PRECISION ONCOLOGY (2021)

添加到收藏夹

Article Engineering, Biomedical

Plasma-enhanced protein patterning in a microfluidic compartmentalized platform for multi-organs-on-chip: a liver-tumor model

Erika Ferrari et al.

Summary: The study introduces a microfluidic technique for micropatterning protein domains and cell cultures within permanently bonded organs-on-chip devices, allowing for the creation of multi-organ in vitro models for drug screening.

BIOMEDICAL MATERIALS (2021)

添加到收藏夹

Review Oncology

Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy

Jasmine Kaur et al.

Summary: Non-small cell lung cancer (NSCLC) is a major concern due to its high mortality and prevalence, making conventional treatment challenging. Developing improved therapeutic treatments like immunotherapy is crucial for specific treatment with minimal damage to healthy tissue. Cancer vaccines show potential for NSCLC treatment, but their efficacy in combination therapy warrants further investigation for future applications.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

TMB in NSCLC: A Broken Dream?

Sara Bravaccini et al.

Summary: TMB, as a potential predictive biomarker for response to immune checkpoint inhibitors, faces limited use in clinical practice due to detection difficulties and various biological, methodological, and economic issues. Combining TMB with PD-L1 expression or other biomarkers in multivariable predictive models could enhance predictive power.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Oncology

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer

Leylah M. Drusbosky et al.

Summary: The MET exon 14 skipping mutation is present in a small percentage of lung cancer patients, but targeted inhibitors like capmatinib and tepotinib show promising clinical activity with tolerable toxicity profiles. Ongoing research aims to overcome acquired resistance and enhance the effectiveness of these agents.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Salidroside inhibits endothelial-mesenchymal transition via the KLF4/eNOS signaling pathway

Yongpan Huang et al.

Summary: This study revealed that SAL may inhibit Hcy-induced EndMT by regulating the KLF4/eNOS signaling pathway, thus improving the development of atherosclerosis.

MOLECULAR MEDICINE REPORTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Toward personalized treatment approaches for non-small-cell lung cancer

Meina Wang et al.

Summary: Over the past two decades, molecular targeted therapies and immunotherapies have significantly improved outcomes for non-small-cell lung cancer (NSCLC), but the majority of advanced NSCLCs eventually become resistant. The future challenge lies in the application of predictive biomarkers for patient stratification in order to better manage NSCLC.

NATURE MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Shun Lu et al.

Summary: The study investigated the activity and safety of savolitinib in patients with pulmonary sarcomatoid carcinoma and other NSCLC subtypes positive for METex14 alterations. Results showed that savolitinib demonstrated promising activity and acceptable safety profile in these patients, suggesting it could be a novel treatment option for this population.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Review Immunology

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

Zhouhong Ge et al.

Summary: TIGIT is an inhibitory receptor expressed on multiple types of lymphocytes, and the efficacy of TIGIT blockade in cancer immunotherapy is currently under investigation. While single TIGIT blockade has limited anti-tumor efficacy, co-blockade with the PD-1/PD-L1 pathway leads to tumor rejection.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Three-Dimensional Vascularized Lung Cancer-on-a-Chip with Lung Extracellular Matrix Hydrogels for In Vitro Screening

Sangun Park et al.

Summary: The study developed a 3D vascularized lung cancer-on-a-chip (VLCC) using sprouting angiogenesis and lung decellularized extracellular matrix to mimic the in vivo cellular microenvironment, showing that drug screening on the VLCC is more effective than on 2D platforms.

CANCERS (2021)

添加到收藏夹

Review Oncology

The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments

Daniel Di Capua et al.

Summary: Liquid biopsies involve isolating and studying tumor cells or cellular components shed into bodily fluids during the development and progression of lung tumors. They have the potential to play a role in lung cancer screening, diagnosis, and providing prognostic information, but also have limitations.

CANCERS (2021)

添加到收藏夹

Review Oncology

RET Inhibitors in Non-Small-Cell Lung Cancer

Priscilla Cascetta et al.

Summary: RET rearrangements in NSCLC act as a potential therapeutic target, with selective RET inhibitors showing higher efficacy rates and good tolerability, providing hope for patients with RET-positive NSCLC. Ongoing phase III clinical trials will definitively establish the efficacy of these inhibitors in RET-positive NSCLC patients.

CANCERS (2021)

添加到收藏夹

Article Cell Biology

Wnt Activity and Cell Proliferation Are Coupled to Extracellular Vesicle Release in Multiple Organoid Models

Gyongyver Orsolya Sandor et al.

Summary: The study revealed a connection between cell proliferation rate and EV release, which could be blocked by Wnt secretion inhibitors. LUAD cells marked by CD133 exhibit malignant behavior.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

添加到收藏夹

Article Oncology

Prospective experimental treatment of colorectal cancer patients based on organoid drug responses

S. N. Ooft et al.

Summary: Organoid technology has emerged as a powerful tool for assessing drug sensitivity in individual patient tumors, potentially offering new avenues for precision medicine. However, in this study, despite some organoids showing drug sensitivity, objective clinical responses were not observed in patients.

ESMO OPEN (2021)

添加到收藏夹

Article Biochemical Research Methods

Cancer drug screening with an on-chip multi-drug dispenser in digital microfluidics

Jiao Zhai et al.

Summary: This paper presents a digital microfluidic system with innovative control structure and chip design for on-chip drug dispensing to generate a wide range of drug concentrations. The system enables single or multi-drug screening with simple electronic control, showing reliability in drug toxicity testing and potential for precision medicine research.

LAB ON A CHIP (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cancer spheroids derived exosomes reveal more molecular features relevant to progressed cancer

Junfang Tu et al.

Summary: Cancer cell spheroids are more physiologically relevant to native tumor tissue than monolayer 2D culture cells, with enhanced intercellular communication and higher exosome production. Exosomal miRNA and GPC-1 expression from spheroids display features relevant to pancreatic cancer progression, potentially highlighting the importance of using spheroids as an in vitro model for cancer research.

BIOCHEMISTRY AND BIOPHYSICS REPORTS (2021)

添加到收藏夹

Article Oncology

Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer

Ruoshi Shi et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer

Jinshuo Fan et al.

GENOMICS (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Towards chamber specific heart-on-a-chip for drug testing applications

Yimu Zhao et al.

ADVANCED DRUG DELIVERY REVIEWS (2020)

添加到收藏夹

Article Oncology

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

J. Mazieres et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

D. Planchard et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

G. R. Oxnard et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Lung-on-a-chip: the future of respiratory disease models and pharmacological studies

Jesus Shrestha et al.

CRITICAL REVIEWS IN BIOTECHNOLOGY (2020)

添加到收藏夹

Article Oncology

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials

Robert C. Doebele et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Biochemical Research Methods

Tumor organoid-T-cell coculture systems

Chiara M. Cattaneo et al.

NATURE PROTOCOLS (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage

Kyu Jin Choi et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2020)

添加到收藏夹

Article Oncology

A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma

Feng Xu et al.

ONCOIMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Shirish Gadgeel et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Cell Biology

Ex-vivo drug testing predicts chemosensitivity in acute myeloid leukemia

Lihui Li et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2020)

添加到收藏夹

Article Oncology

Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment

Lucia Nogova et al.

CANCER MEDICINE (2020)

添加到收藏夹

Review Medicine, General & Internal

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer

Ramon Andrade De Mello et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology

Zahra Dantes et al.

JCI INSIGHT (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening

Zhichao Li et al.

ISCIENCE (2020)

添加到收藏夹

Article Oncology

Genomic characteristics and drug screening among organoids derived fromnon-small celllung cancer patients

Jing-Hua Chen et al.

THORACIC CANCER (2020)

添加到收藏夹

Article Medicine, Research & Experimental

PDX-derived organoids model in vivo drug response and secrete biomarkers

Ling Huang et al.

JCI INSIGHT (2020)

添加到收藏夹

Review Cell Biology

Endothelial-to-Mesenchymal Transition in Cancer

Nicolas Clere et al.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Metastasis-on-a-chip mimicking the progression of kidney cancer in the liver for predicting treatment efficacy

Yimin Wang et al.

THERANOSTICS (2020)

添加到收藏夹

Article Oncology

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

Edward B. Garon et al.

ESMO OPEN (2020)

添加到收藏夹

Review Cell Biology

Regulation of microRNA function in animals

Luca F. R. Gebert et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)

添加到收藏夹

Review Oncology

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

Deborah B. Doroshow et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

GSK-3β regulates the endothelial-to-mesenchymal transition via reciprocal crosstalk between NSCLC cells and HUVECs in multicellular tumor spheroid models

Se-Hyuk Kim et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Critical Care Medicine

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Martin Reck et al.

LANCET RESPIRATORY MEDICINE (2019)

添加到收藏夹

Article Materials Science, Biomaterials

Pleural Effusion Aspirate for Use in 3D Lung Cancer Modeling and Chemotherapy Screening

Andrea Mazzocchi et al.

ACS BIOMATERIALS SCIENCE & ENGINEERING (2019)

添加到收藏夹

Article Oncology

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Ovarian Cancer Treatment Stratification Using Ex Vivo Drug Sensitivity Testing

Ines Lohse et al.

ANTICANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

Carminia Maria Della Corte et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Review Oncology

Endothelial-to-Mesenchymal Transition (EndoMT): Roles in Tumorigenesis, Metastatic Extravasation and Therapy Resistance

Valentin Platel et al.

JOURNAL OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer

Jhanelle E. Gray et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients

Johanne Andersen Hojbjerg et al.

LUNG CANCER (2019)

添加到收藏夹

Review Medicine, General & Internal

Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

Narjust Duma et al.

MAYO CLINIC PROCEEDINGS (2019)

添加到收藏夹

Review Genetics & Heredity

The biogenesis, biology and characterization of circular RNAs

Lasse S. Kristensen et al.

NATURE REVIEWS GENETICS (2019)

添加到收藏夹

Article Cell Biology

Single Cell Mass Cytometry of Non-Small Cell Lung Cancer Cells Reveals Complexity of In Vivo and Three-Dimensional Models over the Petri-Dish

Robert Alfoldi et al.

CELLS (2019)

添加到收藏夹

Review Pathology

NTRK-Fusions - A new kid on the block

Bruno Maerkl et al.

PATHOLOGY RESEARCH AND PRACTICE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening

Minsuh Kim et al.

NATURE COMMUNICATIONS (2019)

添加到收藏夹

Article Multidisciplinary Sciences

3D cell culture stimulates the secretion of in vivo like extracellular vesicles

Sirisha Thippabhotla et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Article Oncology

FLI1 Exonic Circular RNAs as a Novel Oncogenic Driver to Promote Tumor Metastasis in Small Cell Lung Cancer

Lingyu Li et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer

Jiyeon Yun et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Long-term expanding human airway organoids for disease modeling

Norman Sachs et al.

EMBO JOURNAL (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

Masayuki Takeda et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Article Oncology

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

Taofeek K. Owonikoko et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma

Katarina K. Jovanovic et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Review Chemistry, Multidisciplinary

Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies

Xing Chang et al.

RSC ADVANCES (2019)

添加到收藏夹

Article Oncology

Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study

Raimondo Di Liello et al.

ESMO OPEN (2019)

添加到收藏夹

Review Oncology

Modelling cancer in microfluidic human organs-on-chips

Alexandra Sontheimer-Phelps et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Review Oncology

The lung microenvironment: an important regulator of tumour growth and metastasis

Nasser K. Altorki et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Review Oncology

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Ferdinandos Skoulidis et al.

NATURE REVIEWS CANCER (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Min Yuan et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeted therapies for ROS1-rearranged non-small cell lung cancer

T. Patil et al.

DRUGS OF TODAY (2019)

添加到收藏夹

Review Oncology

Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer

Misako Nagasaka et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2018)

添加到收藏夹

Article Oncology

Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer

Rodolfo Bordoni et al.

CLINICAL LUNG CANCER (2018)

添加到收藏夹

Review Oncology

Development of encorafenib for BRAF-mutated advanced melanoma

Peter Koelblinger et al.

CURRENT OPINION IN ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Scott Gettinger et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Targeting the tumour stroma to improve cancer therapy

Kenneth C. Valkenburg et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

A. Drilon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

J. -C. Soria et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations

Lauretta Odogwu et al.

ONCOLOGIST (2018)

添加到收藏夹

Article Oncology

A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer

Gordana Vlahovic et al.

ONCOLOGIST (2018)

添加到收藏夹

Article Cell Biology

Heterogeneity in Lung Cancer

Vitor Manuel Leitao de Sousa et al.

PATHOBIOLOGY (2018)

添加到收藏夹

Article Immunology

A Novel Three-Dimensional Immune Oncology Model for High-Throughput Testing of Tumoricidal Activity

Hilary Sherman et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Combining Extracellular miRNA Determination with Microfluidic 3D Cell Cultures for the Assessment of Nephrotoxicity: a Proof of Concept Study

Laura Suter-Dick et al.

AAPS JOURNAL (2018)

添加到收藏夹

Article Engineering, Biomedical

Bionic 3D spheroids biosensor chips for high-throughput and dynamic drug screening

Qian Wu et al.

BIOMEDICAL MICRODEVICES (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

Krijn K. Dijkstra et al.

CELL (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma

Ines Lohse et al.

PLOS ONE (2018)

添加到收藏夹

Article Oncology

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial

Baohui Han et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Review Medicine, General & Internal

Circular RNAs: Promising Biomarkers for Human Diseases

Zhongrong Zhang et al.

EBIOMEDICINE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Organoid Modeling of the Tumor Immune Microenvironment

James T. Neal et al.

CELL (2018)

添加到收藏夹

Review Oncology

Organoids in cancer research

Jarno Drost et al.

NATURE REVIEWS CANCER (2018)

添加到收藏夹

Article Oncology

Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with resistance to chemotherapy treatment

Silvio Daester et al.

ONCOTARGET (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cell-free DNA in a three-dimensional spheroid cell culture model: A preliminary study

Janine Aucamp et al.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2017)

添加到收藏夹

Article Oncology

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer

Ramaswamy Govindan et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean-Charles Soria et al.

LANCET (2017)

添加到收藏夹

Review Medicine, General & Internal

Lung cancer: current therapies and new targeted treatments

Fred R. Hirsch et al.

LANCET (2017)

添加到收藏夹

Article Oncology

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D. Hellmann et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer

Jane Zhao et al.

LUNG CANCER (2017)

添加到收藏夹

Article Medicine, General & Internal

Tracking the Evolution of Non-Small-Cell Lung Cancer

M. Jamal-Hanjani et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Emmet J. Jordan et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Article Oncology

3D-cultivation of NSCLC cell lines induce gene expression alterations of key cancer-associated pathways and mimic in-vivo conditions

Gabriele Gamerith et al.

ONCOTARGET (2017)

添加到收藏夹

Article Oncology

Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway

Limin Wang et al.

ONCOTARGET (2017)

添加到收藏夹

Review Oncology

Genomic alterations of ERBB receptors in cancer: clinical implications

Rosalin Mishra et al.

ONCOTARGET (2017)

添加到收藏夹

Article Oncology

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

Jean-Pierre Delord et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Review Oncology

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Jonathan C. M. Wan et al.

NATURE REVIEWS CANCER (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Characterization of the cell-free DNA released by cultured cancer cells

Abel Jacobus Bronkhorst et al.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)

添加到收藏夹

Article Oncology

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts

Melanie Mediavilla-Varela et al.

BMC CANCER (2016)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained

Michele Zanoni et al.

SCIENTIFIC REPORTS (2016)

添加到收藏夹

Review Oncology

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines

Raul Barrera-Rodriguez et al.

CANCER CELL INTERNATIONAL (2015)

添加到收藏夹

Article Oncology

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy

Maria Schwaederle et al.

CANCER RESEARCH (2015)

添加到收藏夹

Article Oncology

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

Antonio Calles et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Oncology

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

Nick Thatcher et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Nanoscience & Nanotechnology

Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer

Sara Pignatta et al.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Julie Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Ferdinandos Skoulidis et al.

CANCER DISCOVERY (2015)

添加到收藏夹

Article Oncology

c-MET Inhibitors in the Treatment of Lung Cancer

Joanna Gozdzik-Spychalska et al.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Takashi Seto et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Alterations of LKB1 and KRAS and risk of brain metastasis: Comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma

Ni Zhao et al.

LUNG CANCER (2014)

添加到收藏夹

Article Oncology

Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation

Hiroko Endo et al.

JOURNAL OF THORACIC ONCOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

Alice T. Shaw et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Oncology

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Thomas J. Lynch et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

Julian R. Molina et al.

MAYO CLINIC PROCEEDINGS (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma

Andrey Turchinovich et al.

RNA BIOLOGY (2012)

添加到收藏夹

Article Oncology

The seed and soil hypothesis revisited-The role of tumor-stroma interactions in metastasis to different organs

Robert R. Langley et al.

INTERNATIONAL JOURNAL OF CANCER (2011)

添加到收藏夹

Article Cell Biology

MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins

Kasey C. Vickers et al.

NATURE CELL BIOLOGY (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

Characterization of extracellular circulating microRNA

Andrey Turchinovich et al.

NUCLEIC ACIDS RESEARCH (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma

Jason D. Arroyo et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

添加到收藏夹

Article Biochemical Research Methods

Activity of Anticancer Agents in a Three-Dimensional Cell Culture Model

Victor Sanjit Nirmalanandhan et al.

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2010)

添加到收藏夹

Article Medicine, General & Internal

Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer

Eunice L. Kwak et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Oncology

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer A Systematic Review with Meta-Analysis

Ping Zhan et al.

JOURNAL OF THORACIC ONCOLOGY (2009)

添加到收藏夹

Article Medicine, General & Internal

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker et al.

LANCET (2009)

添加到收藏夹

Article Oncology

Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients The DISTAL-2 randomized trial

Vittorio Gebbia et al.

LUNG CANCER (2009)

添加到收藏夹

Article Medicine, General & Internal

Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.

Tony S. Mok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Review Biophysics

Structure-based view of epidermal growth factor receptor regulation

Kathryn M. Ferguson

ANNUAL REVIEW OF BIOPHYSICS (2008)

添加到收藏夹

Article Multidisciplinary Sciences

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

James Bean et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

添加到收藏夹

Article Oncology

Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts

Elisabeth M. Zeisberg et al.

CANCER RESEARCH (2007)

添加到收藏夹

Review Biochemistry & Molecular Biology

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

M. M. Moasser

ONCOGENE (2007)

添加到收藏夹

Article Medicine, General & Internal

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Alan Sandler et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

添加到收藏夹

Article Oncology

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer

Manuel Hidalgo et al.

CLINICAL CANCER RESEARCH (2006)

添加到收藏夹

Article Medicine, Research & Experimental

Establishment and characterization of multicellular spheroids from a human glioma cell line; Implications for tumor therapy

D Khaitan et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2006)

添加到收藏夹

Article Medicine, General & Internal

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

JH Schiller et al.

NEW ENGLAND JOURNAL OF MEDICINE (2002)

添加到收藏夹

Article Oncology

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens

FV Fossella et al.

JOURNAL OF CLINICAL ONCOLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.